Department of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK 74107, USA; Division of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Health Care Administration, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK 74107, USA.
Immunobiology. 2021 Jan;226(1):152020. doi: 10.1016/j.imbio.2020.152020. Epub 2020 Nov 4.
The bladder epithelial cells elicit robust innate immune responses against urinary tract infections (UTIs) for preventing the bacterial colonization. Physiological fluctuations in circulating estrogen levels in women increase the susceptibility to UTI pathogenesis, often resulting in adverse health outcomes. Dr adhesin bearing Escherichia coli (Dr E. coli) cause recurrent UTIs in menopausal women and acute pyelonephritis in pregnant women. Dr E. coli bind to epithelial cells via host innate immune receptor CD55, under hormonal influence. The role of estrogens or estrogen receptors (ERs) in regulating the innate immune responses in the bladder are poorly understood. In the current study, we investigated the role of ERα, ERβ and GPR30 in modulating the innate immune responses against Dr E. coli induced UTI using human bladder epithelial carcinoma 5637 cells (HBEC). Both ERα and ERβ agonist treatment in bladder cells induced a protection against Dr E. coli invasion via upregulation of TNFα and downregulation of CD55 and IL10, and these effects were reversed by action of ERα and ERβ antagoinsts. In contrast, the agonist-mediated activation of GPR30 led to an increased bacterial colonization due to suppression of innate immune factors in the bladder cells, and these effects were reversed by the antagonist-mediated suppression of GPR30. Further, siRNA-mediated ERα knockdown in the bladder cells reversed the protection against bacterial invasion observed in the ERα positive bladder cells, by modulating the gene expression of TNFα, CD55 and IL10, thus confirming the protective role of ERα. We demonstrate for the first time a protective role of nuclear ERs, ERα and ERβ but not of membrane ER, GPR30 against Dr E. coli invasion in HBEC 5637 cells. These findings have many clinical implications and suggest that ERs may serve as potential drug targets towards developing novel therapeutics for regulating local innate immunity and treating UTIs.
膀胱上皮细胞会针对尿路感染 (UTI) 产生强烈的固有免疫反应,以防止细菌定植。女性循环雌激素水平的生理波动会增加 UTI 发病的易感性,经常导致不良的健康后果。带有 Dr 菌毛的大肠杆菌 (Dr E. coli) 会导致绝经后妇女反复发生 UTI,并导致孕妇急性肾盂肾炎。Dr E. coli 通过受激素影响的宿主固有免疫受体 CD55 与上皮细胞结合。雌激素或雌激素受体 (ER) 在调节膀胱固有免疫反应中的作用尚未完全清楚。在本研究中,我们使用人膀胱上皮癌细胞系 5637 细胞 (HBEC) 研究了 ERα、ERβ 和 GPR30 在调节针对 Dr E. coli 诱导的 UTI 的固有免疫反应中的作用。膀胱细胞中 ERα 和 ERβ 激动剂的治疗通过上调 TNFα 和下调 CD55 和 IL10 诱导对 Dr E. coli 侵袭的保护作用,并且这些作用被 ERα 和 ERβ 拮抗剂逆转。相比之下,GPR30 激动剂介导的激活导致膀胱细胞中固有免疫因子的抑制,导致细菌定植增加,并且这些作用被 GPR30 拮抗剂介导的抑制所逆转。此外,膀胱细胞中 ERα 的 siRNA 介导的敲低通过调节 TNFα、CD55 和 IL10 的基因表达,逆转了在 ERα 阳性膀胱细胞中观察到的对细菌侵袭的保护作用,从而证实了 ERα 的保护作用。我们首次证明,核 ERs(ERα 和 ERβ)而非膜 ER、GPR30 对 HBEC 5637 细胞中 Dr E. coli 侵袭具有保护作用。这些发现具有许多临床意义,并表明 ER 可能作为潜在的药物靶点,用于开发调节局部固有免疫和治疗 UTI 的新型治疗方法。